在晚期黑色素瘤患者中,尼沃卢马布和低分离放射治疗:一项2期试验
Jérôme Doyen1, Anne Dompmartin2, Coralie Cruzel3
1Department of Radiation Oncology, Côte d'Azur University, Antoine Lacassagne Cancer Center, Nice, France.
European journal of cancer (Oxford, England : 1990)
|January 26, 2025
概括
结合放射治疗和尼沃卢马布并没有改善晚期黑色素瘤患者的存活率. 为了在免疫疗法组合中获得更好的结果,需要进一步优化放射治疗计划.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 辐射瘤学 辐射瘤学
背景情况:
- 放射治疗可能会增强抗瘤免疫力,特别是在低分离和多位点输送的情况下.
- 在晚期黑色素瘤中研究将放射治疗与nivolumab结合使用.
研究的目的:
- 评估nivolumab联合和低分离放射治疗在未经治疗的转移性黑色素瘤患者中的疗效.
- 作为主要终点,确定1年整体存活率 (OS).
主要方法:
- 多中心,非随机,第二阶段试验.
- 尼沃卢马布 (240毫克/2周) 加上放射治疗 (6 Gy x 3) 进行.
- 患者在一个或多个目标接受辐射,尽可能.
主要成果:
- 招募了64名患者;中位数随访时间为23.5个月.
- 两年的生存率为65.2%,一年的PFS为56%.
- ECOG-PS得分是OS的独立预后因素;多位点照射和较小的瘤体积与更好的结果相关. 在21.9%的患者中,发生了3-4级不良事件.
结论:
- 与历史数据相比,联合免疫疗法和低分离放射疗法并没有改善生存率.
- 放射治疗计划需要优化,以提高治疗疗效.
- 需要进一步的研究来完善晚期黑色素瘤的组合策略.
相关概念视频
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
01:27Tumor Immunotherapy
466
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
466